Progyny (NASDAQ:PGNY) Upgraded at Leerink Partnrs

Progyny (NASDAQ:PGNY - Get Free Report) was upgraded by research analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating in a research report issued on Tuesday,Zacks.com reports. Leerink Partnrs also issued estimates for Progyny's Q2 2025 earnings at $0.18 EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.64 EPS and FY2026 earnings at $0.98 EPS.

A number of other brokerages also recently weighed in on PGNY. Canaccord Genuity Group cut their target price on Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. Leerink Partners upgraded Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 target price on the stock in a research note on Tuesday. Finally, BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price on the stock in a research note on Monday, March 31st. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $24.09.

Progyny Stock Performance

PGNY traded down $0.40 during midday trading on Tuesday, reaching $23.21. 739,927 shares of the company were exchanged, compared to its average volume of 1,723,180. The company's fifty day moving average price is $21.81 and its 200 day moving average price is $21.58. The company has a market cap of $1.99 billion, a price-to-earnings ratio of 40.72, a price-to-earnings-growth ratio of 2.39 and a beta of 1.31. Progyny has a one year low of $13.39 and a one year high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). The company had revenue of $324.04 million for the quarter, compared to the consensus estimate of $307.86 million. Progyny had a return on equity of 10.90% and a net margin of 4.33%. The business's revenue for the quarter was up 16.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.17 earnings per share. As a group, sell-side analysts anticipate that Progyny will post 0.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Cheryl Scott sold 2,675 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total value of $59,037.25. Following the transaction, the director owned 14,112 shares in the company, valued at approximately $311,451.84. This represents a 15.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.40% of the company's stock.

Hedge Funds Weigh In On Progyny

Several institutional investors have recently bought and sold shares of the company. Leibman Financial Services Inc. raised its holdings in Progyny by 1.1% during the 2nd quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company's stock valued at $1,011,000 after acquiring an additional 513 shares during the period. Voya Investment Management LLC raised its holdings in Progyny by 258.2% during the 1st quarter. Voya Investment Management LLC now owns 185,495 shares of the company's stock valued at $4,144,000 after acquiring an additional 133,703 shares during the period. Militia Capital Partners LP raised its holdings in Progyny by 100.0% during the 1st quarter. Militia Capital Partners LP now owns 2,000 shares of the company's stock valued at $45,000 after acquiring an additional 1,000 shares during the period. Acadian Asset Management LLC raised its holdings in Progyny by 243.6% during the 1st quarter. Acadian Asset Management LLC now owns 205,650 shares of the company's stock valued at $4,589,000 after acquiring an additional 145,802 shares during the period. Finally, Bayforest Capital Ltd bought a new stake in Progyny during the 1st quarter valued at $344,000. Hedge funds and other institutional investors own 94.93% of the company's stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.